TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01201265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg iv every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: to an AUC = 2, on days 1 and 8 of each 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 iv on days 1 and 8 of each 3-week cycle
Study: NCT04377750

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tocilizumab
Description: The placebo treatment arm will include 100 ml of normal saline administered along 60 min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: The placebo treatment arm will include 100 ml of normal saline administered along 60 min
Study: NCT02844647

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperpolarized Pyruvate (13C)
Description: MRI contrast agent
Study: NCT03795597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib is an anti-cancer drug acting as a selective proteasome inhibitor that is used to treat Multiple Myeloma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib is an anti-cancer drug acting as a selective proteasome inhibitor that is used to treat Multiple Myeloma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib is an anti-cancer drug acting as a selective proteasome inhibitor that is used to treat Multiple Myeloma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib is an anti-cancer drug acting as a selective proteasome inhibitor that is used to treat Multiple Myeloma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib is an anti-cancer drug acting as a selective proteasome inhibitor that is used to treat Multiple Myeloma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan IV
Description: Busulfan is an anti-cancer drug acting as a bifunctional alkylating agent that is used to treat Multiple Myeloma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan IV
Description: Busulfan is an anti-cancer drug acting as a bifunctional alkylating agent that is used to treat Multiple Myeloma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan IV
Description: Busulfan is an anti-cancer drug acting as a bifunctional alkylating agent that is used to treat Multiple Myeloma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan IV
Description: Busulfan is an anti-cancer drug acting as a bifunctional alkylating agent that is used to treat Multiple Myeloma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan IV
Description: Busulfan is an anti-cancer drug acting as a bifunctional alkylating agent that is used to treat Multiple Myeloma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan IV
Description: Melphalan is an anti-cancer drug acting as alkylating agent that is used to treat Multiple Myeloma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan IV
Description: Melphalan is an anti-cancer drug acting as alkylating agent that is used to treat Multiple Myeloma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan IV
Description: Melphalan is an anti-cancer drug acting as alkylating agent that is used to treat Multiple Myeloma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan IV
Description: Melphalan is an anti-cancer drug acting as alkylating agent that is used to treat Multiple Myeloma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan IV
Description: Melphalan is an anti-cancer drug acting as alkylating agent that is used to treat Multiple Myeloma.
Study: NCT01572753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 50 ml of water. During the post-dose fasting period of 120 mins, no food or liquid is allowed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 50 ml of water. During the post-dose fasting period of 60 mins, no food or liquid is allowed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 50 ml of water. During the post-dose fasting period of 30 mins, no food or liquid is allowed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 50 ml of water. During the post-dose fasting period of 15 mins, no food or liquid is allowed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 120 ml of water. During the post-dose fasting period of 120 mins, no food or liquid is allowed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 120 ml of water. During the post-dose fasting period of 60 mins, no food or liquid is allowed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 120 ml of water. During the post-dose fasting period of 30 mins, no food or liquid is allowed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 120 ml of water. During the post-dose fasting period of 15 mins, no food or liquid is allowed.
Study: NCT04272086

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 10ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: normal saline
Description: 10ml
Study: NCT03712358

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PVSRIPO
Description: Intralesional injection of PVSRIPO.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PVSRIPO
Description: Intralesional injection of PVSRIPO.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PVSRIPO
Description: Intralesional injection of PVSRIPO.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PVSRIPO
Description: Intralesional injection of PVSRIPO.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PVSRIPO
Description: Intralesional injection of PVSRIPO.
Study: NCT02374450

Intervention type: PROCEDURE
Intervention: Blood collection
Description: For all hospitalised children suspected of having an AESI or meningitis, a sample of 5 ml of whole blood was collected and the serum was stored.

Intervention type: PROCEDURE
Intervention: Blood collection
Description: For all hospitalised children suspected of having an AESI or meningitis, a sample of 5 ml of whole blood was collected and the serum was stored.

Intervention type: PROCEDURE
Intervention: Blood collection
Description: For all hospitalised children suspected of having an AESI or meningitis, a sample of 5 ml of whole blood was collected and the serum was stored.
Study: NCT04379414

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: YES portal
Description: A web-based portal designed for access by smartphone, tablet, or laptop/desktop. The portal is designed to help monitor cancer related issues and to share self-management information, resources and potential research opportunities. The portal is also designed to create a community among participants through the yeschat.org discussion board.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: YES portal
Description: A web-based portal designed for access by smartphone, tablet, or laptop/desktop. The portal is designed to help monitor cancer related issues and to share self-management information, resources and potential research opportunities. The portal is also designed to create a community among participants through the yeschat.org discussion board.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: YES portal
Description: A web-based portal designed for access by smartphone, tablet, or laptop/desktop. The portal is designed to help monitor cancer related issues and to share self-management information, resources and potential research opportunities. The portal is also designed to create a community among participants through the yeschat.org discussion board.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: YES portal
Description: A web-based portal designed for access by smartphone, tablet, or laptop/desktop. The portal is designed to help monitor cancer related issues and to share self-management information, resources and potential research opportunities. The portal is also designed to create a community among participants through the yeschat.org discussion board.
Study: NCT04910789

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transhiatal/transabdominal approach
Description: Radical surgery should be finished via transhiatal/transabdominal approach

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: thoracoabdominal approach
Description: Radical surgery should be finished via thoracoabdominal approach
Study: NCT02325479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enaoxaprin sodium
Description: intrauterine administration after oocyte pickup as the main experimental intervention

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: tissue culture media
Description: intrauterine administration after oocyte pickup as placebo
Study: NCT03011320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC1456
Description: intravenous (IV) bolus dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC1456
Description: intravenous (IV) bolus dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC1456
Description: intravenous (IV) bolus dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC1456
Description: intravenous (IV) bolus dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-Etarfolatide
Description: Injection of unlabeled etarfolatide followed by etarfolatide labeled with 740 to 925 megabecquerels (MBq) \[20 to 25 millicuries (mCi)\] of sodium pertechnetate Tc-99m injection, followed by a single-photon emission tomography (SPECT) or single-photon emission tomography with in-line x-ray computed tomography (SPECT/CT) scan.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-Etarfolatide
Description: Injection of unlabeled etarfolatide followed by etarfolatide labeled with 740 to 925 megabecquerels (MBq) \[20 to 25 millicuries (mCi)\] of sodium pertechnetate Tc-99m injection, followed by a single-photon emission tomography (SPECT) or single-photon emission tomography with in-line x-ray computed tomography (SPECT/CT) scan.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-Etarfolatide
Description: Injection of unlabeled etarfolatide followed by etarfolatide labeled with 740 to 925 megabecquerels (MBq) \[20 to 25 millicuries (mCi)\] of sodium pertechnetate Tc-99m injection, followed by a single-photon emission tomography (SPECT) or single-photon emission tomography with in-line x-ray computed tomography (SPECT/CT) scan.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-Etarfolatide
Description: Injection of unlabeled etarfolatide followed by etarfolatide labeled with 740 to 925 megabecquerels (MBq) \[20 to 25 millicuries (mCi)\] of sodium pertechnetate Tc-99m injection, followed by a single-photon emission tomography (SPECT) or single-photon emission tomography with in-line x-ray computed tomography (SPECT/CT) scan.
Study: NCT00506987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 486757
Description: SCH 486757 2 x 50-mg capsule twice daily orally for 2 weeks followed by a 2-week washout period and 2 weeks of crossover treatment
Study: NCT02030808

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Muscle Relaxants (MR) group
Description: patients received 0.2 mL/kg cisatracurium® (Nimbex) 0.2%, and a left-sided endobronchial double-lumen tube was placed when the TOF revealed one or two twitches

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non- Muscle Relaxants (NMR) group
Description: No cisatracurium® (Nimbex) will be administered
Study: NCT03828825

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patent Foramen Ovale closure
Description: The Patent Foramen Ovale closure is realized under trans-thoracic echocardiography control. If necessary, the operator will use trans-esophageal echocardiography to implant the prosthesis. One day after the procedure, a clinical assessment and an electrocardiogram are performed. At 3 months the consultation corresponds to a trans-thoracic echocardiography validation of the closure accompanied by a bubble test (Valsalva maneuver) and a clinical assessment. At 12 months, the visit corresponds to a consultation with a clinical assessment and an electrocardiogram. At 36-months and 60-months, the visits will be done following the on-site visits provided for in the usual care or during a telephone call from the attending cardiologist to retrieve the results of the clinical examination, electrocardiogram and MACCE (major cardiac and cerebral vascular events). A consultation dedicated to the study may be proposed to patients according to what is provided in the usual care.
Study: NCT01786005

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial magnetic stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Study: NCT03706417

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Telemedicine consult
Description: Utilizing telemedicine in community hospital for earlier identification of symptoms of neonatal encephalopathy.
Study: NCT00852683

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: 75 mg twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 75 mg twice a day
Study: NCT04372381

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcatheter aortic valve replacement (Edwards Sapien Ultra or Medtronic Evolut Pro
Description: Treatment of aortic valve stenosis using transcatheter aortic valve replacement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcatheter aortic valve replacement (Edwards Sapien Ultra or Medtronic Evolut Pro
Description: Treatment of aortic valve stenosis using transcatheter aortic valve replacement
Study: NCT01999881

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise intervention
Description: Receive aerobic and exercise intervention

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard follow-up care
Description: Receive usual care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03077971

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT Self-Help
Description: Self-Help Intervention Workbook using an Acceptance and Commitment Therapy approach

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT Self-Help with Telephone Support
Description: Self-Help Intervention Workbook using an Acceptance and Commitment Therapy approach alongside weekly telephone support calls
Study: NCT03819192

Intervention type: DIAGNOSTIC_TEST
Intervention: microbiome analysis
Description: From all full age pregnant women with PPROM enrolled in this study vaginal smear samples will be taken at three time points:~1. directly after hospitalization~2. 5-7 days after beginning of antibiotic treatment~3. 24 h before birth~The microbiome of the neonates of these women will be analysed out of pharyngeal and rectal swabs and umbilical cord blood taken directly after birth and additionally out of the first Meconium.

Intervention type: DIAGNOSTIC_TEST
Intervention: microbiome analysis
Description: From all full age pregnant women with PPROM enrolled in this study vaginal smear samples will be taken at three time points:~1. directly after hospitalization~2. 5-7 days after beginning of antibiotic treatment~3. 24 h before birth~The microbiome of the neonates of these women will be analysed out of pharyngeal and rectal swabs and umbilical cord blood taken directly after birth and additionally out of the first Meconium.

Intervention type: DIAGNOSTIC_TEST
Intervention: microbiome analysis
Description: From all full age pregnant women with PPROM enrolled in this study vaginal smear samples will be taken at three time points:~1. directly after hospitalization~2. 5-7 days after beginning of antibiotic treatment~3. 24 h before birth~The microbiome of the neonates of these women will be analysed out of pharyngeal and rectal swabs and umbilical cord blood taken directly after birth and additionally out of the first Meconium.

Intervention type: DIAGNOSTIC_TEST
Intervention: Conventional cultures
Description: For every sample taken for microbiome analysis, a conventional culture is taken as control.

Intervention type: DIAGNOSTIC_TEST
Intervention: Conventional cultures
Description: For every sample taken for microbiome analysis, a conventional culture is taken as control.

Intervention type: DIAGNOSTIC_TEST
Intervention: Conventional cultures
Description: For every sample taken for microbiome analysis, a conventional culture is taken as control.

Intervention type: DIAGNOSTIC_TEST
Intervention: CAAP48 measurement
Description: CAAP48 is an identified sepsis marker in adult patients. The samples are taken dependent on clinical monitoring to compare CAAP48 with established inflammation markers (CRP, IL-6, White blood cell count, Procalcitonin).

Intervention type: DIAGNOSTIC_TEST
Intervention: CAAP48 measurement
Description: CAAP48 is an identified sepsis marker in adult patients. The samples are taken dependent on clinical monitoring to compare CAAP48 with established inflammation markers (CRP, IL-6, White blood cell count, Procalcitonin).

Intervention type: DIAGNOSTIC_TEST
Intervention: CAAP48 measurement
Description: CAAP48 is an identified sepsis marker in adult patients. The samples are taken dependent on clinical monitoring to compare CAAP48 with established inflammation markers (CRP, IL-6, White blood cell count, Procalcitonin).
Study: NCT02403128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aflibercept
Description: Intravitreal injection of 2.0 mg aflibercept at baseline, and repeated no sooner than two months from the previous injection for persistent macular edema as defined in the protocol.
Study: NCT02799446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reslizumab
Description: Reslizumab 3mg/kg intravenous (IV)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo intravenous (IV)
Study: NCT03128294

Intervention type: OTHER
Intervention: Retrospective, cross-sectional descriptive analysis
Description: This study is a retrospective, cross-sectional descriptive analysis, and concerns the extraction of data from anonymised patient files. A database will be constructed and descriptive statistics will be used to summarise the data.
Study: NCT02195518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: Tenofovir disoproxil fumarate tablets supplied will be white, almond-shaped, film-coated tablets containing 300 mg of TDF. Each tablet contains the following inactive ingredients: microcrystalline cellulose, lactose monohydrate, pregelatinised starch, croscarmellose sodium, and magnesium stearate.
Study: NCT01517399

Intervention type: DRUG
Group type: OTHER
Intervention: tivantinib
Description: three oral 120 mg tablets administered twice a day

Intervention type: DRUG
Group type: OTHER
Intervention: omeprazole
Description: One 40 mg oral capsule once alone and once again with tivantinib

Intervention type: DRUG
Group type: OTHER
Intervention: s-warfarin
Description: One 10 mg oral tablet once alone and once again with tivantinib

Intervention type: DRUG
Group type: OTHER
Intervention: caffeine
Description: One 200 mg oral tablet once alone and once again with tivantinib

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: vitamin K
Description: One oral 5 mg tablet on multiple days when and around warfarin administration

Intervention type: DRUG
Group type: OTHER
Intervention: digoxin
Description: One oral 0.25 mg tablet once alone and once again with tivantinib
Study: NCT00506987

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Dose 1
Description: Matching placebo capsules twice daily orally for 2 weeks followed by a 2 week washout period and 2 weeks of crossover treatment
Study: NCT04015999

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Microbiota Directed Complementary Food (MDCF)
Description: MDCF2 with four complementary food ingredients (rationale: lead with evidence from Pre-POC clinical trials to optimize lead microbiota-directed complementary food prototypes for their ability to repair microbiota immaturity and positive effects on growth)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ready to Use Supplementary Food (RUSF)
Description: Rice-lentil based RUSF (rationale: reference standard of care for MAM; based on knowledge of its effects on the gut microbiota or microbiota immaturity)
Study: NCT01280110

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxypropylmethylcellulose
Description: 22 patients will receive this lubricating drop 4 times a day for 1 month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboxymethylcellulose
Description: 22 patients will receive this lubricating drop 4 times a day for 1 month.
Study: NCT01517399

Intervention type: DRUG
Group type: OTHER
Intervention: midazolam
Description: Intravenous 1.5 mg dose once alone and once again with tivantinib